RCUS
Income statement / Annual
Last year (2024), Arcus Biosciences, Inc.'s total revenue was $258.00 M,
an increase of 120.51% from the previous year.
In 2024, Arcus Biosciences, Inc.'s net income was -$283.00 M.
See Arcus Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$258.00 M |
$117.00 M |
$112.00 M |
$383.00 M |
$78.00 M |
$15.00 M |
$8.35 M |
$1.41 M |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.31 M
|
| Gross Profit |
$258.00 M
|
$117.00 M
|
$112.00 M
|
$383.00 M
|
$78.00 M
|
$15.00 M
|
$8.35 M
|
$1.41 M
|
-$1.31 M
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
| Research and Development Expenses |
$448.00 M
|
$340.00 M
|
$288.00 M
|
$257.00 M
|
$159.00 M
|
$78.48 M
|
$49.65 M
|
$47.22 M
|
$14.25 M
|
| General & Administrative Expenses |
$120.00 M
|
$117.00 M
|
$104.00 M
|
$72.00 M
|
$43.00 M
|
$25.23 M
|
$13.57 M
|
$7.64 M
|
$3.94 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$120.00 M
|
$117.00 M
|
$104.00 M
|
$72.00 M
|
$43.00 M
|
$25.23 M
|
$13.57 M
|
$7.64 M
|
$3.94 M
|
| Other Expenses |
$20.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$588.00 M
|
$457.00 M
|
$392.00 M
|
$329.00 M
|
$202.00 M
|
$103.71 M
|
$63.21 M
|
$54.85 M
|
$18.18 M
|
| Cost And Expenses |
$588.00 M
|
$457.00 M
|
$392.00 M
|
$329.00 M
|
$202.00 M
|
$103.71 M
|
$63.21 M
|
$54.85 M
|
$18.18 M
|
| Interest Income |
$52.00 M
|
$41.00 M
|
$16.00 M
|
$1.00 M
|
$1.00 M
|
$5.20 M
|
$4.92 M
|
$775.00 K
|
$212.00 K
|
| Interest Expense |
$4.00 M
|
$2.00 M
|
$2.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$10.00 M
|
$8.00 M
|
$6.00 M
|
$4.00 M
|
$3.00 M
|
$3.58 M
|
$3.66 M
|
$2.61 M
|
$1.31 M
|
| EBITDA |
-$269.00 M |
-$291.00 M |
-$258.00 M |
$59.00 M |
-$120.00 M |
-$81.13 M |
-$51.20 M |
-$50.83 M |
-$16.87 M |
| EBITDA Ratio |
-1.04
|
-2.49
|
-2.3
|
0.15
|
-1.54
|
-5.41
|
-6.13
|
-35.97
|
0
|
| Operating Income Ratio |
-1.28
|
-2.91
|
-2.5
|
0.14
|
-1.59
|
-5.91
|
-6.57
|
-37.82
|
0
|
| Total Other Income/Expenses Net |
$47.00 M
|
$39.00 M
|
$14.00 M
|
$1.00 M
|
$1.00 M
|
$4.00 M
|
$5.27 M
|
$359.00 K
|
$212.00 K
|
| Income Before Tax |
-$283.00 M
|
-$301.00 M
|
-$266.00 M
|
$55.00 M
|
-$123.00 M
|
-$84.71 M
|
-$49.59 M
|
-$53.08 M
|
-$17.97 M
|
| Income Before Tax Ratio |
-1.1
|
-2.57
|
-2.38
|
0.14
|
-1.58
|
-5.65
|
-5.94
|
-37.57
|
0
|
| Income Tax Expense |
$1.00 M
|
$6.00 M
|
$1.00 M
|
$2.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$283.00 M
|
-$307.00 M
|
-$267.00 M
|
$53.00 M
|
-$123.00 M
|
-$84.71 M
|
-$49.59 M
|
-$53.08 M
|
-$17.97 M
|
| Net Income Ratio |
-1.1
|
-2.62
|
-2.38
|
0.14
|
-1.58
|
-5.65
|
-5.94
|
-37.57
|
0
|
| EPS |
-3.14 |
-4.15 |
-3.71 |
0.76 |
-2.13 |
-1.73 |
-1.43 |
-2.16 |
-0.73 |
| EPS Diluted |
-3.14 |
-4.15 |
-3.71 |
0.71 |
-2.13 |
-1.73 |
-1.43 |
-2.16 |
-0.73 |
| Weighted Average Shares Out |
$90.10 M
|
$74.00 M
|
$72.00 M
|
$69.35 M
|
$54.79 M
|
$43.83 M
|
$34.62 M
|
$24.55 M
|
$24.55 M
|
| Weighted Average Shares Out Diluted |
$90.10 M
|
$74.00 M
|
$72.00 M
|
$73.97 M
|
$54.79 M
|
$43.83 M
|
$34.62 M
|
$24.55 M
|
$24.55 M
|
| Link |
|
|
|
|
|
|
|
|
|
